IE59292B1 - Liver fluke antigens - Google Patents
Liver fluke antigensInfo
- Publication number
- IE59292B1 IE59292B1 IE324785A IE324785A IE59292B1 IE 59292 B1 IE59292 B1 IE 59292B1 IE 324785 A IE324785 A IE 324785A IE 324785 A IE324785 A IE 324785A IE 59292 B1 IE59292 B1 IE 59292B1
- Authority
- IE
- Ireland
- Prior art keywords
- juvenile
- antigen
- fasciola
- antiserum
- antigens
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 126
- 102000036639 antigens Human genes 0.000 title claims abstract description 124
- 108091007433 antigens Proteins 0.000 title claims abstract description 124
- 241000242711 Fasciola hepatica Species 0.000 title claims abstract description 22
- 208000006275 fascioliasis Diseases 0.000 title abstract description 18
- 230000000366 juvenile effect Effects 0.000 claims abstract description 93
- 241000242541 Trematoda Species 0.000 claims abstract description 46
- 239000012634 fragment Substances 0.000 claims abstract description 15
- 230000000890 antigenic effect Effects 0.000 claims abstract description 14
- 229960005486 vaccine Drugs 0.000 claims abstract description 12
- 239000002671 adjuvant Substances 0.000 claims abstract description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 208000031513 cyst Diseases 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 6
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- 230000003302 anti-idiotype Effects 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 30
- 241001494479 Pecora Species 0.000 abstract description 14
- 102000004169 proteins and genes Human genes 0.000 abstract description 13
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 241000283690 Bos taurus Species 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 238000000760 immunoelectrophoresis Methods 0.000 abstract description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 5
- 244000045947 parasite Species 0.000 abstract description 4
- 238000009987 spinning Methods 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 241000282849 Ruminantia Species 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 241000415078 Anemone hepatica Species 0.000 description 20
- 208000015181 infectious disease Diseases 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 11
- 101710132348 Flagellar regulator flk Proteins 0.000 description 10
- 241000935974 Paralichthys dentatus Species 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 229960001614 levamisole Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012146 running buffer Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 4
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229920002306 Glycocalyx Polymers 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 210000000013 bile duct Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000004517 glycocalyx Anatomy 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000237858 Gastropoda Species 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 208000025011 Distomatosis Diseases 0.000 description 2
- 241000585116 Galba truncatula Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 241000242678 Schistosoma Species 0.000 description 2
- 229940122760 T cell stimulant Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000008004 immune attack Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000186581 Clostridium novyi Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000204939 Fasciola gigantica Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102000018690 Trypsinogen Human genes 0.000 description 1
- 108010027252 Trypsinogen Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- WMGWLIAIMDFMIQ-UHFFFAOYSA-N sulfuroiodidic acid Chemical compound OS(I)(=O)=O WMGWLIAIMDFMIQ-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/43559—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from trematodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848432401A GB8432401D0 (en) | 1984-12-21 | 1984-12-21 | Liver fluke antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE853247L IE853247L (en) | 1986-06-21 |
| IE59292B1 true IE59292B1 (en) | 1994-02-09 |
Family
ID=10571591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE324785A IE59292B1 (en) | 1984-12-21 | 1985-12-19 | Liver fluke antigens |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4743446A (de) |
| EP (1) | EP0211001B1 (de) |
| AU (2) | AU5310286A (de) |
| DE (1) | DE3583341D1 (de) |
| GB (2) | GB8432401D0 (de) |
| IE (1) | IE59292B1 (de) |
| NZ (1) | NZ214652A (de) |
| WO (1) | WO1986003680A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346953A1 (de) * | 1983-12-24 | 1985-08-14 | Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg | Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung |
| WO1988001277A1 (en) * | 1986-08-18 | 1988-02-25 | The Australian National University | Helminth parasite vaccine |
| BR9007070A (pt) * | 1989-01-31 | 1991-11-12 | Daratech Pty Ltd | Vacina para o tratamento preventivo de infeccao por vermes trematoides do figado em ruminantes |
| US5650154A (en) * | 1989-02-01 | 1997-07-22 | Theresia Meeusen; Elza Nicole | Protective antigens against disease pathogens |
| JPH08502404A (ja) * | 1992-10-21 | 1996-03-19 | マリンクロット ベテリナリー，アイエヌシー， | チオールプロテアーゼを含有するワクチン |
| AU5996294A (en) * | 1993-02-05 | 1994-08-29 | Daratech Pty Ltd | Polypeptides obtainable from species of fasciola, and vaccines, methods of treatment and DNA sequences of the same |
| CN1132514A (zh) * | 1993-09-28 | 1996-10-02 | 墨尔本大学 | 针对寄生虫的保护性抗原 |
| US6017757A (en) * | 1997-02-20 | 2000-01-25 | Mississippi State University | Isolated viable nematode intestinal cells |
| NZ337697A (en) * | 1997-03-11 | 2001-06-29 | Stichting Dienst Landbouwkundi | An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method |
| US7273479B2 (en) * | 2003-01-15 | 2007-09-25 | Cryodynamics, Llc | Methods and systems for cryogenic cooling |
| CN102811732B (zh) | 2009-12-10 | 2016-02-17 | 科英布拉农业大学 | 免疫原、组合物及其用途和制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314992A (en) * | 1978-11-08 | 1982-02-09 | Bitakaramire Peter K | Process for producing fascioliasis vaccine |
| IL63224A (en) * | 1980-07-17 | 1985-05-31 | Scripps Clinic Res | Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom |
| US4416866A (en) * | 1981-08-28 | 1983-11-22 | The Johns Hopkins University | Diagnosis and treatment of fluke infections with monoclonal antibodies |
| JPS60155133A (ja) * | 1983-11-09 | 1985-08-15 | シンビオテイツクス コ−ポレイシヨン | アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン |
| CA1256795A (en) * | 1983-12-28 | 1989-07-04 | Dennis A. Carson | Anti-idiotype antibodies induced by synthetic polypeptides |
-
1984
- 1984-12-21 GB GB848432401A patent/GB8432401D0/en active Pending
-
1985
- 1985-12-19 IE IE324785A patent/IE59292B1/en not_active IP Right Cessation
- 1985-12-20 AU AU53102/86A patent/AU5310286A/en not_active Abandoned
- 1985-12-20 NZ NZ214652A patent/NZ214652A/xx unknown
- 1985-12-20 US US06/897,534 patent/US4743446A/en not_active Expired - Fee Related
- 1985-12-20 WO PCT/GB1985/000594 patent/WO1986003680A1/en active IP Right Grant
- 1985-12-20 GB GB08531375A patent/GB2169606B/en not_active Expired
- 1985-12-20 EP EP86900214A patent/EP0211001B1/de not_active Expired - Lifetime
- 1985-12-20 DE DE8686900214T patent/DE3583341D1/de not_active Expired - Lifetime
-
1990
- 1990-06-13 AU AU57098/90A patent/AU619682B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| NZ214652A (en) | 1988-09-29 |
| GB2169606B (en) | 1988-12-14 |
| US4743446A (en) | 1988-05-10 |
| AU5310286A (en) | 1986-07-22 |
| GB8432401D0 (en) | 1985-02-06 |
| AU619682B2 (en) | 1992-01-30 |
| IE853247L (en) | 1986-06-21 |
| GB8531375D0 (en) | 1986-02-05 |
| AU5709890A (en) | 1990-10-04 |
| DE3583341D1 (de) | 1991-08-01 |
| GB2169606A (en) | 1986-07-16 |
| EP0211001B1 (de) | 1991-06-26 |
| WO1986003680A1 (en) | 1986-07-03 |
| EP0211001A1 (de) | 1987-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blaser et al. | Campylobacter jejuni-specific serum antibodies are elevated in healthy Bangladeshi children | |
| Urban Jr et al. | Ascaris suum: protective immunity in pigs immunized with products from eggs and larvae | |
| Hillyer et al. | Identification of a 17-kilodalton Fasciola hepatica immunodiagnostic antigen by the enzyme-linked immunoelectrotransfer blot technique | |
| Dunne et al. | Human antibody responses to Schistosoma mansoni: the influence of epitopes shared between different life‐cycle stages on the response to the schistosomulum | |
| HU215245B (hu) | Eljárás a humán interleukin-4 (IL-4) polipeptidek, ezekkel termelt antitestek és az antitesteket tartalmazó gyógyszerkészítmények előállítására | |
| Iglesias et al. | Anisakis simplex: antigen recognition and antibody production in experimentally infected mice | |
| Raizman et al. | Detection of circulating antigen in acute experimental infections with Toxoplasma gondii | |
| US4743446A (en) | Liver fluke antigens derived from juvenile fasciolo organisms | |
| Estévez et al. | Monoclonal antibodies to turbot (Scophthalmus maximus) immunoglobulins: characterization and applicability in immunoassays | |
| Ruppel et al. | Schistosoma mansoni: immunoblot analysis of adult worm proteins | |
| Ingram et al. | The immune response of the brown trout Salmo trutta to lipopolysaccharide | |
| Bromage et al. | Antibody structural variation in rainbow trout fluids | |
| Lorenzen et al. | Antibody response to VHS virus proteins in rainbow trout | |
| Yakoleff-Greenhouse et al. | Analysis of antigenic variation in cysticerci of Taenia solium | |
| KR910005702B1 (ko) | 말라리아 기생충에 대한 방어항체를 유도하는 폴리펩티드 단편을 함유한 면역원 조성물의 제조방법 | |
| O'Donnell et al. | Characterization of the major immunogen in the excretory-secretory products of exsheathed third-stage larvae of Trichostrongylus colubriformis | |
| KR20100139096A (ko) | 조성물, 방법 및 키트 | |
| Hillyer et al. | Immunoprecipitins in Schistosoma mansoni infections: I. Mouse infections | |
| Sudjarwo et al. | Purification and characterization protein of anti-dengue specific immunoglobulin Y for diagnostic kit of dengue | |
| Abdolmaleki et al. | Evaluation of human anti IgG polyclonal antibody production conjugated with peroxidase in egg yolk | |
| Estevez et al. | A sandwich immunoassay to quantify low levels of turbot (Scophthalmus maximus) immunoglobulins | |
| Cazabonne et al. | Kinetics study and characterisation of target excreted/secreted antigens of immunoglobulin G, M, A and E antibodies from mice infected with different strains of Toxoplasma gondii | |
| Wang et al. | Phage displaying peptides mimic schistosoma antigenic epitopes selected by rat natural antibodies and protective immunity induced by their immunization in mice | |
| Tanaka et al. | Schistosoma: a 200-kDa chemotherapeutic target antigen is differentially localized in African vs Oriental species | |
| DE60030443T2 (de) | Synthetische peptide die immunoreaktivität gegen den virus von hepatitis a zeigen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |